Hepatitis C virus infection in hemodialyzed patients

International Journal of Artificial Organs

Volumn 30, Issue 2, 2007, Pages 100-107

  Li Vecchi, M ^a   La Spada, E ^b   Li Vecchi, V ^a   Montalto, Giuseppe ^b,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Cattedra di Medicina Interna   (Italy)

Author keywords

Antiviral therapy; Epidemiology; Hemodialyzed patients; Hepatitis C virus

Indexed keywords

PATIENT TREATMENT; VIRUSES;

ANTIVIRAL THERAPY; CLINICAL COURSE; GENERAL POPULATION; HEMODIALYSIS PATIENT; HEMODIALYZED PATIENT; HEPATITIS C VIRUS; INFECTED PATIENTS; LIVER DISEASE; MORTALITY RATE; VIRUS INFECTION;

DIALYSIS;

ALPHA INTERFERON; AMINOTRANSFERASE; CREATININE; ERYTHROPOIETIN; HEMOGLOBIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; RIBAVIRIN;

ANEMIA; ANTIVIRAL THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIARRHEA; DISEASE SEVERITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FOLLOW UP; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER DISEASE; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MORTALITY; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; UNSPECIFIED SIDE EFFECT; VITAMIN DEFICIENCY;

EID: 34147184403     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880703000204     Document Type: Review

References (52)

1. Jadoul M, Poignet JL, Gedds C, Locatelli F, Medin C, Krajewska M, and the HCV collaborative group. The changing epidemiology of hepatitis C virus infection in haemodialysis: European multicentre study. Nephrol Dial Transplant 2004; 19: 904-9.
2. Conway M, Catterall AP, Brown EA, Tibbs C, Gower PE, Curtis JR, Coleman JC, Murray-Lyon IM. Prevalence of antibodies to hepatitis C in dialysis patients and transplant recipients with possible routes of trasmission. Nephrol Dial Transplant 1992; 7: 1226-9.
3. Jerome B, Zeldis, TA, Depner IK, Kuramoto BS, Gish RG, Holland PV. The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med 1990; 112: 958-60.
4. Pol S, Legendre C, Saltiel C, Carnoit F, Brechot C, Berthelot P, Mattlinger B, Nenri Kkreis H. Hepatitis C virus in kidney recipients. J Hepatol 1992; 15: 202-6.
5. Fujiyama S, Kawana S, Sato S, Tanaka M, Goto M, Taura Y, Sato T, Kawahara T, Mizuno K. Prevalence of hepatitis C virus antibodies in hemodialysis patients and dialysis staff. Hepato-Gastroenterol 1992; 39: 161-5.
6. Morikawa T, Nakata K, Hamasaki K, Tsuruta S, Kkato Y, Nakao K, Ohtsubo T, Eguchi K. Prevalence and characterization of hepatitis C virus hemodialysis patients. Intern Med 1999; 38: 626-31.
7. Tsuyuguchi M. Prevalence of hepatitis C virus infection among chronic haemodialysis patients. Hokkaido Igaku Zasshi 1994; 69: 1178-88.
8. Mitwalli AH, Alam A, Al-Wakeel J, Al Suwaida K, Tarif N, Schaar TA, Al Adbha B, Hammad D. Effect of chronic viral hepatitis on graft survival in Saudi renal transplant patients. Nephron Clin Pract 2006; 102: 72-80.
9. Olut Al, Ozsakarya F, Dilek M. Seroprevalence of hepatitis C virus infection and evaluation of serum aminotransferase levels among hemodialysis patients in Izmir, Turkey. J Int Med Res 2005; 33: 641-6.
10. Valderrabano F, Jones EP, Mallick NP. Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant 1995; 10 (suppl 5): S1-2.
11. Geerlings W, Tufveson G, Ehrich JH, et al. Report on management of renal failure in Europe, XXIII. Nephrol Dial Transplant 1994; 9 (suppl 1): S6-25.
12. Soresi M, Montalto G, Galione A, et al. Prevalenza di anticorpi anti-HCV in una popolazione di emodializzati siciliani. Rec Progr Med 1994; 85: 415-8.
13. Izopet J, Sandres-Saune K, Kamar N, Salama G, Dubois M, Pasquier C, Rosaing L. Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol 2005; 77: 70-6.
14. Fabrizi F, De Vecchi AF, Como G, Lunghi G, Martin P. De novo HCV infection among dialysis patients: a prospective study by HCV core antigen ELISA assay. Ailment Pharmacol Ther 2005: 21: 861-9.
15. Schneeberge PM, Keur I, van Loon AM, Mortier D, de Coul OK, Verschuuren-van Haperen A, Sanna R, van der Heijden TG, van den Hoven H, van Hamersvelt HW, Quint W, van Doorn L-J. The prevalence and incidence of hepatitis C infections among dialysis patients in the Netherlands: a nation wide prospective study. J Infect Dis 2000; 182: 1291-9.
16. Espinosa M, Martin-Malo A, Ojeda R, Santamariaa R, Soriano S, Aguera M, Aljama P. Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients. Causes and consequences. Am J Kidney Dis 2004; 43: 685-9.
17. Hmaied F, Mamou MB, Saune-Sandres K, Rostaing L, Slim A, Arrouji Z, Redjeb SB, Izopet J. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. J Med Virol 2006; 78: 185-91.
18. Kumagai J, Komiya Y, Tanaka J, Katayama K, Tatsukawa Y, Yorioka N, Miyakawa Y, Yoshizawa H. Hepatitis C virus infection in 2,744 hemodialysis patients followed regularly at nine centers in Hiroshima during November 1999 through February 2003. J Med Virol 2005; 76: 498-502
19. Dentico P, Buongiorno R, Volpe A, Corleone A, Carbone M, Manno C, Proscia F, Pastore G, Schiraldi O. Prevalence and incidence of hepatitis C virus (HCV) in hemodialysis patients: study of risk factors. Clin Nephrol 1992; 38: 49-52
20. Dentico P, Buongiorno R, Volpe A, Corleone A, Carbone M, Manno C, Proscia F, Pastore G, Schiraldi O. Detection of antibodies to HCV in haemodialysis patients using two second generations ELISA test. Ital J Gastroenterol 1993; 25: 19-22.
21. Tsuyugushi M. Prevalence of hepatitis C virus infection among chronic hemodialysis patients. Hokkaido Igaku Zasshi 1994; 69: 1178-88.
22. Fabrizi F, Poodard F, Martin P. Hepatitis C infection and the patient with end stage renal disease. Hepatology 2002; 36: 3-10.
23. Badalamenti S, Catania A, Lunghi G, et al. Changes in viremia and circulating interferon alpha during hemodialysis in hepatitis C virus positive patients: only coincidental phenomena? Am J Kidney Dis 2003; 42: 143-50.
24. Yasuda K, Okuda K, Endo N, Ishiwatari Y, Ikeda R, Hayashi H, Yokozeki K, Koboyashi S, Irie Y. Hypoaminotrasferasemia in patients undergoing long-term haemodialisys: clinical and biochemical appraisal. Gastroenterology 1995; 109: 1295-300.
25. Guh JY, Lai YH, Yang CY, Chen SC, Chuang WL, Hsu TC, et al. Impact of decreased serum transaminase levels on the evalution of viral hepatitis in hemodialysis patients. Nephron 1995; 69: 459-65.
26. Fabrizi F, Lunghi G, Andrulli S, Pagliari B, Mangano S, Faranna P et al. influence of hepatitis C virus viremia upon serum aminotransferase activity in chronic dialysis patients. Nephrol Dial Transplant 1997; 12: 1394-98.
27. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Soriano S, Aljama P. High ALT levels predict viremia in anti-HCV positive HD patients if a modified normal range of ALT is applied. Clin Nephrol 2000; 54: 151-56.
28. Boyacioglu S, Gur G, Ylmaz U, et al. Investigation of possible clinical and laboratory predictors of liver fibrosis in hemodialysis patients infected with hepatitis C virus. Transplant Proc 2004; 36: 50-2.
29. Martin P, Carter D, Fabrizi F, et al. Histo-pathological features of hepatitis C in renal transplant candidates. Transplantation 2000; 15: 1479-84.
30. Nakayama E, Akiba T, Marumo F, et al. Prognosis of antihepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000: 11: 1896-902.
31. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004: 20: 1271-7.
32. Kalantar-Zadeh K, Mc Allister CJ, Miller LG. Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a populations based study. Nephrol Dial Transplant 2005; 20: 1662-69.
33. Morales JM. Hepatitis C virus infection and renal disease after renal transplantation. Transplant Proc 2004; 36: 760-2.
34. Mathurin P, Mouquet C, Poynard T et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-63.
35. Andriulii A, Festa V, Leandro G, Rizzetto M. Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection. Dig Dis Sci 2001; 46: 1409-15.
36. Gentil M, Rocha JL, Rodriguez-Algarra G, et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999; 14: 2455-60.
37. Bucci JR, Matsumoto CS, Swanson SJ, et al. Donor C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 2002; 13: 2974-82.
38. Gane E, Pilmor H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74: 427-37.
39. Fabrizi F, Bunnapradist S, Lunghi G, Martin P. Transplantation of kidneys from HCV-positive donors: a safe strategy? J Nephrol 2003; 16: 617-25.
40. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Metanalysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Al Pharmacol Ther 2003; 18: 1071-81.
41. Russo MW, Goldsweig CD, Jacobson I, Brown RS. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98: 1610-15.
42. Kamar N, Topance O, Buchler M, Izope J, Sandres-Saune K, Durand D, Rostaing L. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 2092-8.
43. Magnone M, Holley JL, Shapiro R, et al. Interferon alpha induced acute renal allograft rejection. Transplantation 1995; 59: 1068-70.
44. Lamb M, Marks IM, Wynohradnyk L, et al. Peginterferon alfa-2a, 40 kDa Pegasys can be administered safely in patients with end stage renal disease. Hepatology 2001; 34: 326A.
45. Gupta SK, Glue P, Jacobs S, et al. Single dose pharmacokinetics and tolerability of pegylated interferon alpha 2b in young and elederlyhealthy subjects. Br J Pharmacol 2003; 56: 131-34
46. Annicchiarico BE, Siciliano M. Pegylate interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C. Ailment Pharmacol Ther 2004: 20: 123-124
47. Teta D, Luscher BL, Gonvers JJ, Francioli P. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 2005; 20: 991-3.
48. Kokoglu OF, Ucmac H, Hosoglu S et al. Efficacy and tolerability of peylated interferon alpha 2a in hemodialysis patients with chronic hepatitis C. J Clin Gastroenterol 2006; 21: 575-80.
49. Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha 2b monotherapy in hemodialyzed patients with chronic hepatitis C. Nephrol Dial Transplant 2006; 21: 437-43.
50. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004; 36: 1831-4.
51. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection. A pilot study. J Viral Hepat 2001; 8: 287-92.
52. Bruchfeld A, Lindahl K, Reichard O, et al. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006; 13. 316-21.